ACIM
WST icon

Azimuth Capital Investment Management’s West Pharmaceutical WST Stock Holding History

Azimuth Capital Investment Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,813
Closed -$9.44M – 307
2024
Q4 		$9.44M Sell
28,813
-94
-0.3% -$29.6K 0.37% 91
2024
Q3 		$8.68M Sell
28,907
-1,550
-5% -$475K 0.34% 102
2024
Q2 		$10M Sell
30,457
-569
-2% -$201K 0.41% 74
2024
Q1 		$12.3M Sell
31,026
-1,536
-5% -$568K 0.51% 63
2023
Q4 		$11.5M Sell
32,562
-266
-0.8% -$94.1K 0.52% 65
2023
Q3 		$12.3M Sell
32,828
-196
-0.6% -$75.8K 0.61% 55
2023
Q2 		$12.6M Sell
33,024
-472
-1% -$169K 0.6% 54
2023
Q1 		$11.6M Sell
33,496
-1,550
-4% -$453K 0.57% 59
2022
Q4 		$8.25M Buy
35,046
+9,222
+36% +$2.19M 0.42% 74
2022
Q3 		$6.36M Buy
25,824
+306
+1% +$93.2K 0.35% 102
2022
Q2 		$7.72M Buy
+25,518
New +$8.3M 0.39% 87

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Azimuth Capital Investment Management's WST Position: Q1 2025 in Review

Azimuth Capital Investment Management sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 28,813 shares — an estimated $9.44M sold.

Azimuth Capital Investment Management first reported a position in WST in Q2 2022 and held it in 11 quarters. The position peaked at $12.6M in Q2 2023. 714 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Azimuth Capital Investment Management reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Azimuth Capital Investment Management sold 28,813 West Pharmaceutical shares in Q1 2025, an estimated $9.44M.
  • Azimuth Capital Investment Management first reported a position in West Pharmaceutical in Q2 2022 and held it in 11 quarters.
  • Azimuth Capital Investment Management's West Pharmaceutical position peaked at $12.6M in Q2 2023.
  • 714 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Azimuth Capital Investment Management's 13F filing for Q1 2025, filed 13 May 2025.